155 related articles for article (PubMed ID: 2511818)
21. Similar mechanism of various lupus anticoagulants.
Exner T
Thromb Haemost; 1985 Feb; 53(1):15-8. PubMed ID: 3922078
[TBL] [Abstract][Full Text] [Related]
22. Unveiling the complex effects of direct oral anticoagulants on dilute Russell's viper venom time assays.
Hillarp A; Strandberg K; Gustafsson KM; Lindahl TL
J Thromb Haemost; 2020 Aug; 18(8):1866-1873. PubMed ID: 32294291
[TBL] [Abstract][Full Text] [Related]
23. Effect of lupus anticoagulants on the activated partial thromboplastin time. Results of the College of American Pathologists survey program.
Brandt JT; Triplett DA; Rock WA; Bovill EG; Arkin CF
Arch Pathol Lab Med; 1991 Feb; 115(2):109-14. PubMed ID: 1899555
[TBL] [Abstract][Full Text] [Related]
24. The dilute phospholipid APTT: a sensitive assay for verification of lupus anticoagulants.
Alving BM; Baldwin PE; Richards RL; Jackson BJ
Thromb Haemost; 1985 Oct; 54(3):709-12. PubMed ID: 3937268
[TBL] [Abstract][Full Text] [Related]
25. Heterogeneity of lupus anticoagulant (LA) antibodies: LA activity in dilute Russell's Viper Venom Time and dilute Kaolin Clotting Time detect different populations of antibodies in patients with the "antiphospholipid" syndrome.
Kandiah DA; Krilis SA
Thromb Haemost; 1998 Aug; 80(2):250-7. PubMed ID: 9716148
[TBL] [Abstract][Full Text] [Related]
26. Comparison of four laboratory tests for lupus anticoagulant.
Stark RA; Gordon S
Pathology; 1990 Apr; 22(2):122-3. PubMed ID: 2122400
[TBL] [Abstract][Full Text] [Related]
27. Prothrombin time, activated partial thromboplastin time and dilute Russell's Viper Venom times are not shorter in patients with the prothrombin G20210A mutation, and dilute Russell's Viper Venom time may be longer.
Shirts BH; Rodgers GM; Smock KJ
Thromb Res; 2012 Sep; 130(3):e134-8. PubMed ID: 22542363
[TBL] [Abstract][Full Text] [Related]
28. A new-generation dilute Russell's viper venom time assay system for lupus anticoagulants: evaluation of detection utilising frozen reagents and controls.
Moore GW; Tugnait S; Savidge GF
Br J Biomed Sci; 2005; 62(3):127-32. PubMed ID: 16196459
[TBL] [Abstract][Full Text] [Related]
29. Further evidence of false negative screening for lupus anticoagulants.
Moore GW; Henley A; Greenwood CK; Rangarajan S
Thromb Res; 2008; 121(4):477-84. PubMed ID: 17602725
[TBL] [Abstract][Full Text] [Related]
30. Quantitative Risk for Single-Positive Lupus Anticoagulant Results With Different Anticoagulants.
Khan W; Tormey CA; Rinder HM; Siddon AJ
Am J Clin Pathol; 2023 May; 159(5):417-419. PubMed ID: 36940149
[TBL] [Abstract][Full Text] [Related]
31. Testing strategies for diagnosing lupus anticoagulant: decision analysis.
Segal JB; Lehmann HP; Petri M; Mueller L; Kickler TS
Am J Hematol; 2002 Jul; 70(3):195-205. PubMed ID: 12111765
[TBL] [Abstract][Full Text] [Related]
32. Taipan snake venom time coupled with ecarin time enhances lupus anticoagulant detection in nonanticoagulated patients.
Moore GW; Culhane AP; Maloney JC; Archer RA; Breen KA; Hunt BJ
Blood Coagul Fibrinolysis; 2016 Jun; 27(4):477-80. PubMed ID: 26656903
[TBL] [Abstract][Full Text] [Related]
33. Comparison of six dilute russell viper venom time lupus anticoagulant screen/confirm assay kits.
McGlasson DL; Fritsma GA
Semin Thromb Hemost; 2013 Apr; 39(3):315-9. PubMed ID: 23468380
[TBL] [Abstract][Full Text] [Related]
34. Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I.
Arnout J; Meijer P; Vermylen J
Thromb Haemost; 1999 Jun; 81(6):929-34. PubMed ID: 10404770
[TBL] [Abstract][Full Text] [Related]
35. Warfarin does not interfere with lupus anticoagulant detection by dilute Russell's viper venom time.
Olteanu H; Downes KA; Patel J; Praprotnik D; Sarode R
Clin Lab; 2009; 55(3-4):138-42. PubMed ID: 19462936
[TBL] [Abstract][Full Text] [Related]
36. Utilization of dilute Russell's viper venom time to detect autoantibodies against beta 2-glycoprotein I which express anticoagulant activity in the presence but not in the absence of exogenous phospholipids.
Pengo V; Balestrieri G; Tincani A; Spatola L; Biasiolo A; Brocco T
Thromb Haemost; 1997 Jan; 77(1):123-6. PubMed ID: 9031461
[TBL] [Abstract][Full Text] [Related]
37. The diagnosis of lupus anticoagulants by the activated partial thromboplastin time--the central role of phosphatidyl serine.
Kelsey PR; Stevenson KJ; Poller L
Thromb Haemost; 1984 Oct; 52(2):172-5. PubMed ID: 6441303
[TBL] [Abstract][Full Text] [Related]
38. The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile.
Galli M; Finazzi G; Norbis F; Marziali S; Marchioli R; Barbui T
Thromb Haemost; 1999 May; 81(5):695-700. PubMed ID: 10365739
[TBL] [Abstract][Full Text] [Related]
39. The dilute Russell's viper venom time.
Radhakrishnan K
Methods Mol Biol; 2013; 992():341-8. PubMed ID: 23546726
[TBL] [Abstract][Full Text] [Related]
40. [Comparative multicenter study of a rabbit high-sensitivity thromboplastin and a recombinant thromboplastin with synthetic phospholipids].
Martínez-Brotóns F; Borrell M; Fontcuberta J; Batlle J; López F; Páramo JA; Ribera C; Rocha E; Vicente V; Zuazu I
Sangre (Barc); 1994 Aug; 39(4):245-51. PubMed ID: 7985052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
